Quoc Le-Nguyen
Chief Tech/Sci/R&D Officer bij 89BIO, INC.
Vermogen: 3 M $ op 29-02-2024
Profiel
Currently, Quoc Le-Nguyen is Chief Technical Operations Officer & Head-Quality at 89bio, Inc.
He previously was Vice President-Manufacturing Operations at Bayer AG and SVP, Global Head-Technical Operations & Quality at Aduro BioTech, Inc.
He received an undergraduate degree from the University of California.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
89BIO INC
0.24% | 17-02-2024 | 222 149 ( 0.24% ) | 3 M $ | 29-02-2024 |
Actieve functies van Quoc Le-Nguyen
Bedrijven | Functie | Begin |
---|---|---|
89BIO, INC. | Chief Tech/Sci/R&D Officer | 01-03-2019 |
Eerdere bekende functies van Quoc Le-Nguyen
Bedrijven | Functie | Einde |
---|---|---|
CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01-07-2018 |
BAYER AG | Corporate Officer/Principal | 01-09-2013 |
Opleiding van Quoc Le-Nguyen
University of California | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BAYER AG | Health Technology |
89BIO, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Aduro BioTech, Inc.
Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |